Liquid Blood Biopsy and Early Cancer Detection

Authors:

D. James Morré, Brandon Hostetler, David J. Taggart, Dorothy M. Morré, A. W. Musk, Bruce W. S. Robinson, and Jenette Creaney

ENOX2-based early detection (Oncoblot) of asbestos-induced malignant mesothelioma 4-10 years in advance of clinical symptoms

This article describes Liquid Biopsy & Stage Zero Cancer

Stage Zero cancer refers to the presence of disease as detected by liquid biopsy, but prior to the presentation of clinically assessed cancer via PET/CT or MRI scans, or via tissue biopsy.

While using blood tests to detect disease is not particularly new or novel, applying this to detecting cancer prior to its presentation clinically, is relatively new.

Liquid Biopsy refers to using a blood test to gain an insight into the state of cancer, in a similar fashion to extracting a tissue sample and performing a pathological analysis on it would.

Interestingly, the body of research which attempts to tackle the detection of cancer very early on is populated with some fascinating insights.

Specifically, the use of ENOX2 as a biomarker for early disease detection has produced some compelling results, as evidenced here:

FULL ARTICLE